# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Craig-Hallum analyst Chase Knickerbocker maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price targ...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corpo...
Oppenheimer analyst Francois Brisebois maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Outperform and raises the price...
HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price t...
Piper Sandler analyst David Amsellem maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Overweight and raises the price t...
Needham analyst Ami Fadia maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $20 to ...